An assessment of the frequency of blood transfusion before and after starting hydroxyurea therapy in children of sickle cell anemia

Shikha Gupta¹, Prachi Chaudhary², Amrita Chauhan³, Preeti Malpani⁴

¹Post Graduate Resident, ²Associate Professor, ³Senior Resident, ⁴Professor, Department of Paediatrics, Mahatma Gandhi Memorial Medical College, Indore, Madhya Pradesh, India

ABSTRACT

Background: Hydroxyurea therapy is a known effective and safe therapy for the treatment of sickle cell anemia (SCA). Although it is used worldwide in our Madhya Pradesh based setup, it is underutilized due to economic reasons and unaware practitioners about its use. Aims and Objectives: The objective of the study is to assess the frequency of blood transfusion year before and after starting hydroxyurea therapy in children of SCA. Materials and Methods: An ambispective observational study was performed at MGM Medical College Indore over a period of 1 year 8 months. One hundred and ninety patients were enrolled after taking a complete history, then started on Hydroxyurea and followed up every 2 months till 1 year. On follow-up, frequency of blood transfusion was noted along with routine investigations and for any side effects. Results: Of 190 total recruited patients, 84 were studied at the end because of loss to follow-up due to various reasons. Significant decrease in the need for blood transfusion was observed within 1 year of starting Hydroxyurea (P<0.05). Conclusion: The use of hydroxyurea in our native population at our setup can decrease the need for frequent blood transfusion in sickle cell patients.

Key words: Sickle cell anemia and hydroxyurea; Hydroxyurea and blood transfusion; Blood transfusion in sickle cell anemia; Drugs for sickle cell anemia.

INTRODUCTION

Sickle cell anemia (SCA) is a type of hemoglobinopathy which is a group of blood disorders affecting the structure, function, or production of hemoglobin (Hb). These conditions are usually autosomal recessive inherited and may range from asymptomatic laboratory abnormalities to death in utero. Sickle cell disease (SCD) is caused by a mutation in beta-globin gene that changes the sixth amino acid to valine resulting in HbS. Inheritance of HbS from one parent and another hemoglobinopathy from another parent results various sickle cell syndromes (for e.g., beta-thalassemia). In India, SCD is a common hemoglobinopathy, next to thalassemia.

This variant Hb polymerizes abnormally rendering red blood corpuscles easily deformable, sticky, and shape like a sickle which abnormally adheres to the endothelium of small venules. These abnormal red blood cells (RBCs) promote unpredictable episodes of microvascular vaso-occlusion and premature RBC destruction (hemolytic anaemia). Prominent manifestations include episodes of ischemic pain and ischemic or frank infarction within the spleen, central nervous system, bones, liver, kidneys, and lungs.¹

The prevalence of carrier state of sickle cell varies from 1% to 40% among different tribal groups. Madhya Pradesh has the maximum load with an estimated number of 67,861
sickle homozygote and 9, 61,492 sickle heterozygote. Out of 45 districts in Madhya Pradesh, 27 districts fall into sickle cell belt.

The prevalence of sickle cell varies from 10% to 33% in Madhya Pradesh. It has also been estimated that 13,432 pregnancies would be at risk of getting a toddler with SCD in Madhya Pradesh and thus the expected annual births of sickle homozygote would be 3358.

Although the SCD is present from birth, symptoms are rare before the age of the 3–6 months with an increased incidence of adverse events coincident with the physiologic fall in fetal Hb (Hbf). SCA was first described in south Indian tribal groups and subsequently in central India. Vaso-occlusive pain episodes are one of the most common clinical features associated with SCA.

Bone marrow transplantation is only cure for SCD, which usually necessitates a human lymphocyte antigen-identical family member donor. There is 85% disease-free survival rate, 3 with a 7% transplant-related mortality rate and a 9% graft failure rate. Barriers to the widespread use of bone marrow transplantation in patients with SCD include a scarcity of suitable bone marrow donors and therefore the got to identify patients with an adequate risk-to-benefit ratio.

For these reasons, drug therapy for SCD continues to be the first and primary mode of disease management that specialize in decreasing the complications of this disease.

Hydroxyurea, a myelosuppressive agent, is that the only effective drug proven to decrease the frequency of painful episodes. It raises the extent of Hbf and thus the Hb level. It was first tested in SCD in 1984. It generally reduces the rate of painful crisis by 50%. It also reduces the rate of blood transfusions and acute chest syndrome episodes by ~50% in adults. It was developed as an anticancer drug and is also been used to treat myeloproliferative disorders-leukemia, melanoma, and ovarian cancer.

Side effects; includes anorexia, nausea, vomiting, low absolute neutrophil count (ANC), bone marrow suppression, elevation of liver enzymes, and infertility.

The phase 3 NHLBI—sponsored multicentre study of hydroxyurea trial proved clinical efficacy for preventing acute vaso-occlusive crisis in severely affected adults. Based on this cumulative evidence, hydroxyurea has emerged as a valuable therapeutic option for children and adolescents with frequent vaso occlusive events; recent evidence documents sustained long-term benefits with prevention or reversal of chronic organ damage.

Although questions remain regarding its long-term risks and benefits, the current study is conducted to analyze clinico-hematological response in patients of SCD receiving hydroxyurea.

Rationale
Hydroxyurea therapy is a known effective and safe therapy for treatment of SCA, although it is used worldwide in our MP based setup it is underutilized because of high cost, unawareness, and unrealistic fear among health care workers regarding its use in SCD, along with this inconsistent medical delivery system also contribute to less frequent use of Hydroxyurea in our setup.

Aims and objectives
To study the frequency of blood transfusion year before and after starting hydroxyurea therapy in children of SCA.

MATERIALS AND METHODS
The present study was carried out at MGM medical college Indore from January 2019 to August 2020. After taking written informed consent from the parents, the patients with SCD were included in the study population.

Source of data
All patients attending Dept. of Paediatrics, M.Y Hospital, Indore and Chacha Nehru Bal Chikitsalaya Evam Anusandhan Kendra, Indore.

The study sample was based on the prevalence of SCD, in Madhya Pradesh. Minimal sample size was required in the study was 100.

Study design
Retrospective and prospective (ambispective) observational study.

Inclusion criteria
• Diagnosed cases of SCD by Hb electrophoresis.

Exclusion criteria
• Patients <2 years of age
• HIV reactive patients
• Patients already on hydroxyurea therapy before enrolment were excluded.

A detailed history, clinical examination, and specific baseline investigations (Complete blood count [CBC], liver function test [LFT], renal function test [RFT], HIV, Hb electrophoresis), were done before starting Hydroxyurea therapy detailed history questionnaire and Medical records used to know age, sex, caste, age of diagnosis, and frequency of blood transfusion/year.
The typical starting dose of hydroxyurea was 15–20 mg/kg/day and doses were adjusted according to ANC (target to be maintained between 2000 and 2500). Then patients were called for follow-up every 2 months till 1 year.

On follow-up, frequency of blood transfusion was noted. On follow-up specific investigations including CBC, RFT, and LFT done. On each follow up if any, side effects were investigated.

If neutropenia <1500/ul and thrombocytopenia <80,000 occurs, hydroxyurea therapy was withheld and monitor CBC with white blood count differentially. When blood counts recover, reinstitute hydroxyurea therapy. Data analyzed as pre-treatment and post-treatment of hydroxyurea therapy.

Statistical analysis
The data were collected from the proforma of the study and then was compiled in the Microsoft Excel software for the master chart. Statistical Package for the Social Sciences (SPSS) version 22 (IBM SPSS Statistics, Somers NY, USA) was used to analyze data. Chi-square test, Wilcoxon Signed Rank test, Friedman test, and unpaired t-test was used to calculated P-value.

RESULTS
During the study 190 sickle cell patients were recruited for our study.

- Total recruited patients = 190
- Lost to follow-up = 106
- Study population at 12 months = 84 (out of which 57 were SCA and 27 were SCD).

Out of 84 patients, 34 were male and 46 were female.

Interpretation
This table shows that the majority of sickle cell patient in our study belong to 6–10 year of age (Table 1).

<table>
<thead>
<tr>
<th>Age</th>
<th>No of patients</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>1–5 year</td>
<td>10</td>
<td>11.9</td>
</tr>
<tr>
<td>6–10 year</td>
<td>42</td>
<td>50</td>
</tr>
<tr>
<td>11–15 year</td>
<td>24</td>
<td>28.6</td>
</tr>
<tr>
<td>&gt;15 year</td>
<td>8</td>
<td>9.5</td>
</tr>
<tr>
<td>Total</td>
<td>84</td>
<td>100.0</td>
</tr>
</tbody>
</table>

Table 2: Frequency of blood transfusion/year before and after hydroxyurea therapy

<table>
<thead>
<tr>
<th>Variable</th>
<th>n</th>
<th>Mean</th>
<th>SD</th>
<th>Minimum</th>
<th>Maximum</th>
<th>95% confidence Interval</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood transfusion before hydroxyurea</td>
<td>84</td>
<td>5.36</td>
<td>4.59</td>
<td>0</td>
<td>12</td>
<td>Lower-4.078</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Blood transfusion after hydroxyurea</td>
<td>84</td>
<td>0.32</td>
<td>0.75</td>
<td>0</td>
<td>3</td>
<td>Upper-6.007</td>
<td></td>
</tr>
</tbody>
</table>
A study by Agrawal et al.,\textsuperscript{7} (after Hydroxyurea therapy need for blood transfusion decreases by 50\%) and Ana Cristina Silva-Pinto I (RBC units transfused decreased from 1.23±2.25 to 0.1±0.3, \(P=0.0051\)), similar outcome was observed and it stated that Hydroxyurea decreases the need for blood transfusion.\textsuperscript{7,11}

This decrease in need of RBC units' transfusion in our study may be due to rise in Hb level associated with Hydroxyurea therapy and decreased hemolysis.

Limitations of the study
As the patients come to our setup from distant places, loss to follow up was a major setback because of distance as well as economic constraints for travelling.

CONCLUSION
In our study, we enrolled 121 patients out of which only 84 were able to complete the scheduled follow-up at regular interval of 2 months, i.e., 2, 4, 6, 8, 10, and 12 month. We recorded the baseline value of blood transfusions/year.

We followed the patients at regular interval of 2 months and the above mentioned parameter was compared with the baseline parameter.

It was found that there was a significant reduction in the rate of blood transfusion/year, and thus leading to decreased morbidity with prolonged survival.\textsuperscript{1} So after evaluating the above data, we could conclude that Hydroxyurea is an effective in reducing frequency of blood transfusion in SCA and sickle-\(\beta\) Thalassemia disease. Thus based on the above study, we can recommend regular use of hydroxyurea in our native population at our setup in Indore.

ACKNOWLEDGMENT
A sincere thanks to the Day Care Centre staff nurses and technicians to help us complete the study as well the Department of Pediatrics of our centre.

REFERENCES
Authors Contribution:
SG- Concept and design of the study, statistical analysis and interpretation; PC- Interpreted the results; reviewed the literature and manuscript preparation; PM- Concept, coordination; AC- Prepared the first draft of manuscript, preparation of manuscript and revision of the manuscript.

Work attributed to:
Mahatma Gandhi Memorial Medical College, Indore - 452 001, Madhya Pradesh, India.

Orcid ID:
Dr. Amrita Chauhan- https://orcid.org/0000-0001-5791-3626
Dr Shikha Gupta- https://orcid.org/0000-0002-5126-7536
Dr Prachi Chaudhary- https://orcid.org/0000-0002-4548-4411
Dr Preeti Malpani- https://orcid.org/0000-0002-9039-2970

Source of Support: None. Conflicts of Interest: None.